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Abstract
Background: The effects of psychotropic drugs on cardiac repolarization have increasingly
gained attention in research and clinical practice over the last 2 decades. The absolute risk of
cardiac arrhythmia, such as the polymorphic ventricular tachycardia, Torsades de Pointes (TdP),
is low (14 per 10,000 patients/year) and sudden cardiac death as a consequence of all cardiac
arrhythmias is less frequent (Braillon et al., 2017). TdP can occur at therapeutic doses of secondgeneration antipsychotics and antidepressants and with a corrected Q-T (QTc) interval >500 ms.
Many psychotropic medications can delay cardiac repolarization thereby producing prolonged
QTc in the electrocardiogram (ECG). Emergency departments (EDs) are a frequent point of care
for patients diagnosed with psychiatric medical disorders taking one or more psychotropic
medications.
Purpose of Project: Using evidence-based practice, this project standardize the cardiac
assessment of psychiatric patients in the ED who were on one or more psychotropic medications
by performing a 12-lead ECG on arrival to rule out QTc prolongation, thus reducing the risk of
polymorphic ventricular tachyarrhythmia.
Outcomes: Fifty patient-ECGs were evaluated and compared by psychotropic medication; all
were within normal range. Recommend continuance of ECG protocol to assess for the possibility
of QTc prolongation and to prevent its progression to TdP.
Keywords: Psychotropic medications, psychiatric medications, QT prolongation, QTc
prolongation, 12-lead ECG, emergency department, Torsades de Pointes.
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Impact of Psychotropic Medications on Electrical Cardiac
Conduction in the Emergency Department: A Best Practice Review
Description of the Clinical Problem
The effect of psychotropic drugs on cardiac repolarization has increasingly gained
attention in research and clinical practice over the last two decades. A prolonged QTc may in
rare cases contribute to TdP emergence and, while often self-limited, could progress to
ventricular fibrillation and sudden cardiac death. Of the psychotropic drugs, antipsychotics and
some antidepressants have both been proven to increase QTc and are associated with TdP and
sudden cardiac death.
Prior to a drug’s approval, the U.S. Food and Drug Administration (FDA) requires
manufacturers to perform comprehensive investigations on the medication side-effects profile to
include evaluation of QT and QTc prolongation risks. The most commonly known drug-induced
mechanism of QT prolongation occurs when the inward rectifier potassium (I Kr) channel of
cardiomyocytes is inhibited, thus resulting in delayed cardiac action potential. First generation
antipsychotics (i.e., dopamine antagonists, neuroleptics) were primarily used to treat
schizophrenia and other psychotic disorders, as well as thioridazine (Mellaril, Mellaril-S),
pimozide (Orap), and haloperidol (Haldol, Haldol Decanoate, Peridol) have all been found to
prolong the QTc. Selective serotonin reuptake inhibitors (SSRIs) have been controversial in their
effects on the QTc, leading the FDA to perform random crossover studies to compare the effects
of citalopram (Celexa) to its S-isomer escitalopram (Cipralex, Lexapro), as well as to sertraline
(Zoloft). Results of these case studies indicated that fluoxetine (Prozac) could protect against
post-MI cardiovascular events including arrhythmias. Women demonstrated a significantly more

PSYCHOTROPIC DRUGS AND QTc IN THE ED

4

pronounced prolongation in the QTc interval than men; however, men typically had a longer
QTc.
TdP is a potentially dangerous side effect of several psychotropic medications but is
difﬁcult to study because of its low rate of occurrence. The absolute risk of cardiac arrhythmia,
such as Torsades de Pointes (TdP) is low (14 per 10,000 patients) annually, while sudden cardiac
death as a consequence of all cardiac arrhythmias occurs even less frequently (Braillon et al.,
2017). TdP can occur at therapeutic doses of second-generation antipsychotics and
antidepressants and with a corrected QT (QTc) interval >500 ms. Many psychotropic
medications can delay cardiac repolarization, thereby producing a prolonged QTc in the
electrocardiogram (ECG). In rare cases, a prolonged QTc may cause life-threatening
polymorphic ventricular tachyarrhythmia such as TdP. TdP is often self-limited but may lead to
ventricular fibrillation and sudden cardiac death.
The QT interval is a measure of combined cardiac depolarization and repolarization
(Postema & Wilde, 2014). The QT interval starts with the beginning of the QRS-complex (i.e.,
ventricular depolarization) and ends with termination of the T-wave (i.e., ventricular
repolarization). QTc prolongation is defined as > 450 ms for men and > 470 ms for women
(Goldenberg et al, 2013). In healthy adults, a mean QTc prolongation of > 5 ms due to
medication is cause for concern in toxicity studies (Hasnain & Vieweg, 2014). Proven to prolong
QTc and associated with TdP and sudden cardiac death are psychotropic drugs, antipsychotics,
and some antidepressants. These antidepressants include the classes of conventional
antipsychotics, dopamine stabilizers, serotonin antagonist/reuptake inhibitors, noradrenergic and
specific serotonergic antidepressants, norepinephrine and dopamine reuptake inhibitors, selective
norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, serotonin-dopamine
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antagonists, serotonin and norepinephrine reuptake inhibitors, serotonin 1A partial agonists,
serotonin partial agonist reuptake inhibitors, and tricyclic/tetracyclic antidepressants. The
emergency department (ED) frequently serves as a point of care for patients diagnosed with
psychiatric medical disorders taking prescribed psychotropic medications.
Numerous study designs, to include meta-analyses, systematic reviews, randomized
controlled studies, case-control and cross-sectional studies, have justified concerns regarding the
risk of prolonged QTc, prompting regulatory agencies such as the USA Federal Drug
Administration (FDA) to investigate this side effect of prescribed medications to monitor their
safety. Several factors are considered when analyzing the effect of QTc prolongation, including
age (< or > 60 years); sex; metabolic inhibition of another drug (e.g., CYP2C19 inhibitors) or
those of who are poor CYP2C19 metabolizers; hepatic impairment; concurrent use of another
QTc-prolonging drug (Hasnain et al, 2013); cardiac disease (e.g., congestive heart failure),
cardiac structural or electrical abnormalities or coronary heart disease; congenital long QT
syndrome (Arizona University-based Center for Education and Research on Therapeutics
[AZCERT],n.d.), hypomagnesemia; and hypokalemia. AZCERT’s CredibleMeds website was
accessed to identify second- generation antidepressants (SGAD) and second-generation
antipsychotics (SGAP) medications. Attention was focused on psychotropic medications that
caused prolongation of the QT/QTc interval and sudden cardiac death; seven SGADs (i.e.,
citalopram, escitalopram, fluoxetine, mirtazapine, paroxetine, sertraline, venlafaxine) and nine
SGAPs (i.e., amisulpride, clozapine, iloperidone, olanzapine, paliperidone, quetiapine,
risperidone, sertindole, ziprasidone. Haloperidol (Haldol) is a common first-generation
antipsychotic (FGAP) in use that has been found to potentiate QTc prolongation.
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The American Heart Association (AHA) and the American College of Cardiology
Foundation (ACCF) released a scientific statement to raise awareness among health care
professionals about the risk, ECG monitoring, and management of drug-induced QT interval
prolongation and TdP in hospitalized patients. This statement emphasized the importance of
awareness of risk factors in order to minimize the likelihood of occurrence of drug-induced TdP
(Drew et al., 2010). In a 5-year cross-sectional ECG screening in 6,790 adult psychiatric
inpatients, 27.3% had abnormal ECGs, 1.6% had long QT, and 0.95% qualified as drug-induced
long QT case subjects. Sudden cardiac death was recorded in five patients and TdP was recorded
in seven other patients (Girardin et al., 2013).
Currently, there is a paucity of national or international guidelines or consensus
documents with specific recommendations regarding ECG monitoring and screening for
antidepressant and antipsychotic treatment. Existing guidance typically recommends ECG
monitoring and screening before and during the start of psychotropic medicines known to cause
QTc prolongation in those vulnerable to CYP2C19 inhibitors or metabolizers. The Food and
Drug Administration (FDA, 2012) issued a warning about the SGAD citalopram (Celexa) and its
potential risk for QTc prolongation leading to TdP at doses greater than 40 mg orally. Newer
product labeling urged providers to use lower doses, to not exceed 20 mg in patients older than
60 years of age, in patients with hepatic dysfunction, those who were poor CYP219
metabolizers, and those taking concomitant CYP2C19 inhibitors. Due to this warning, the
maximum dose of citalopram changed to 40 mg daily in nonelderly persons (Forest
Pharmaceuticals, Inc, 2012). Antidepressant use has increased in 2017-2018 from 10.6% to
13.8% in the United States (Brody & Gu, 2020). More than 34.4 million adults took
antidepressants in 2014, up from 13.4 million in 2010, and over 242 million U.S. adults filled
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one or more prescriptions for psychiatric medications (Moore & Mattison, 2017). With the
SARS-CoV-2 pandemic, mental health demand has increased in the United States by over 40.9%
during the month of June 2020, when compared to June 2019. The impact of stay-at-home
orders, social distancing, loss of employment and wages, and stresses on care providers and
loved ones have contributed to a 30.9% increase in reported symptoms of anxiety and depressive
disorders, a 26.3% increase in trauma or stressor-related disorders, a 13.3%, increase in
substance use to cope with the stress or emotions related to SARS-CoV-2, and a 10.7% increase
in the admitted incidence of suicidal ideations (Czeisler et al, 2020).
According to the Centers for Disease Control and Prevention (CDC, n.d.), an estimated
50% of Americans will be diagnosed with a mental illness or disorder at some point in their
lifetime. Depression is the third most common cause of hospitalizations in the United States for
those aged 18 years-44 years old. For providers who prescribe the use of psychotropic
medications to treat mental illness, careful consideration needs to be given to rare but serious
side effects.
Evidence-Based Practice Model
Across the educational pavé, numerous evidence-based practice models guide the
registered nurse and advanced practice registered nurse. For this DNP project, the John Hopkins
Nursing Evidence-Based Practice Model (JHNEBP) was selected to guide decision-making
(Dang & Dearholt, 2017). The JHNEBP model is a three-step process that involves a crossexamination in clinical practice, searching for the best scientific evidence, then translating
evidence into current practice in order to improve patient care.
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Evidenced-Based Solutions
Review of the literature was performed using the following search engines: CINAHL,
Cochrane, Evidence-Based Medical Reviews, Google Scholar, PsycARTICLES, PsychINFO,
and PubMed. Keywords utilized during initial and later searches were psychotropic medications,
psychiatric medications, QT prolongation, QTc prolongation, drug-induced QT interval
prolongation, 12-lead ECG, ED, ventricular dysrhythmia, polymorphic ventricular
tachyarrhythmia, Torsades de Pointes, sudden cardiac death, first generation
antipsychotics/antidepressants, second generation antipsychotics/antidepressants, psychiatric
diagnosis, mental health in EDs. This search yielded 93 articles from the last 8 years. To narrow
the search further, Medical Subject Headings (MeSH) terminology that were used included
psychotropic medications, polymorphic ventricular tachyarrhythmia, ED, prolonged QTc, and
12-lead ECG, which yielded 51 results. These searches were performed multiple times between
January 2020 and January 2021. A total of 22 articles were critically appraised to evaluate the
proposed intervention for this manuscript. The articles were selected based on their quality,
relevance to their population, and English language.
Purpose of the EBP Project
The purpose of this Doctor of Nursing (DNP) project was to (a) conduct an evidencebased meta-analysis and literature reviews concerning QTc-prolongation due to psychotropic
medications, (b) recommend the performance of 12-lead ECGs on persons diagnosed with a
psychiatric disorder between the ages of 18 years and 65 years of age, and (c) evaluate the
outcomes for patients meeting the recommended guidelines. This project’s intent was to educate
emergency physicians and nurses to obtain 12-lead ECGs on patients prescribed psychiatric
medications and to analyze the QT and QTc prolongations due to risk factors.
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Project Site
This project was conducted in an ED located in Southern California. The hospital did not
have a standardized protocol for patients taking psychotropic medications. Annually, the ED
admitted 560 adult patients (18 years-65 years of age) who were evaluated for a psychiatric
disorder, including suicidal ideations, attempts, self-harm, overdose, and assaults.
Project Implementation Timeline
Development started January 2020 with the research Clinical Mentor to define the DNP
project goals of analyzing and assessing QTc prolongation in patients currently prescribed with
psychotropic medications. A literature review was done to obtain the most recent meta-analyses
of evidence-based research on psychiatric medications with current FDA concerns for QT/QTc
prolongations. The ED Physicians supported this DNP project with full collaboration as each
psychiatric patient on psychotropic medications was seen, assessed, and evaluated for QTc
prolongation.
Barriers to this project included the delayed from midyear to the end of the year 2020
attributable to the SARS-CoV-2 global pandemic and all of its uncertainties. One form of
resistance the ED/Trauma director faced was the unforeseen pandemonium that devastated the
country at a startling rate, paralyzing the project’s start. Once stability was achieved, all
stakeholders agreed to pursue the project in earnest. In the meantime, an education plan and
protol were developed. To monitor the outcomes of patients seen in the ED who fulfilled criteria,
a data plan was devised.
Education Plan/Protocol
If a patient presented to the ED and acknowledged taking a psychotropic medication, the
12-lead ECG was ordered to assess for prolonged QTc or abnormal arrhythmia. If positive, the
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ED physician or registered nurse educated the patient and/or family members or contacted the
psychiatrist or primary care provider.
Data Plan/Design
An Excel spreadsheet was created including age, sex, psychiatric diagnosis, psychotropic
medication(s), QTc measured in milliseconds (ms), and cardiac rhythm.
Updated literature reviews were conducted in late 2020 while awaiting IRB review and
permission to proceed was obtained in January 2021. The progress of the project is outlined in
Table 1.
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Table 1
Project Development and Implementation Timeline
Intervention/Activities
Engaged mentorship of Dr. Kelsoe at
University of California, of San
Diego Psychiatry and he was
amenable
Proposal of DNP Practice project to
Inland Valley Medical Center
Emergency Department

Persons Involved

Timeline

DNP Student
Dr. John Kelsoe, MD

December 12, 2019

DNP Student
Jennifer Lee, MSN, RN

January 10, 2020

Clinical Stakeholders Presentation
scheduled to present DNP Practice
project

DNP Student
Jennifer Lee, MSN, RN.
ED Directors
ED Physicians

March 30, 2020

SARS-COV-2 Global Pandemic
postponement

DNP Student
Jennifer Lee, MSN, RN
ED Directors
ED Physicians

March 19, 2020

University of California, San Diego
IRB acceptance letter

DNP Student
Dr. John Kelsoe, MD

September 25, 2020

Inland Valley Medical Center ED
IRB acceptance letter

DNP Student
Dr. Craig Owens, MD

January 13, 2021

University of San Diego IRB
acceptance letter

DNP Student
Michael Terry, DNP, PMHNP, FNP
Joseph Burkard, DNSc, CRNA

January 13, 2021

Dissemination of final results at
clinical stakeholder presentation

DNP Student
Jennifer Lee, MSN, RN
ED Directors
ED Physicians

March 1, 2021

Final dissemination of final
manuscript and poster presentation at
the University of San Diego

DNP Student
USD Hahn School of Graduate
Nursing

March 4, 2021

Graduate

DNP Student
USD Hahn School of Graduate
Nursing

May 22, 2021

Project Impact and Cost Benefit Analysis
The average cost for a 12-lead ECG in an ED setting in the United States was estimated
between $50 - $150. The ED where this DNP project was performed charged $150 per 12-lead
ECG. In 2017, mental and substance use disorder (MSUD) ED visits had service delivery costs
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of more than $5.6 billion; more than 7% percent of total ED-visit costs ($76.3 billion).
According to Karaca and Moore (2020), the average cost was $1,500 per ED visit across the 10.7
million MSUD ED visits, similar to the $3,000 average cost for all 144.8 million ED visits.
The rate of ED visits for mental health and substance use diagnoses increased 44.1%
from 2006 to 2014, to a rate of 20.3 visits per 1,000 population (Karaca & Moore, 2020).
According to the most recent census, the population in Riverside County in 2019 was 2,470,546
people (U.S. Census Bureau, 2020). At this size, it can be estimated that an average of 50,152
ED visits were for psychiatric diagnoses. Additionally, up to 27% of ED visits in the United
States could be managed in the lower-cost setting of physician offices, clinics, and urgent care
centers (Weinick et al, 2016). If a 12-lead ECG was performed during a psychiatric patient’s
visit to the ED, patients with prolonged QTc could as the result of medication be identified,
preventing ED visits and managed by physician offices, clinics, and urgent care centers.
As stated above, the average cost of a 12-lead ECG at this DNP project’s ED is $150.
With 50,152 psychiatric ED visits per year, the total costs for all visits is $75,228,000. If a 12lead ECG was running for each visit, it would cost $7,522,800. If 27% of ED visits could be
regulated by physician offices, clinics, and urgent care centers, it would prevent 13,541 yearly
visits to the ED. By reducing these visits, it would save $20,311,560 in emergency visit costs
yielding a total cost avoidance to the ED of $67,705,200. These costs do not include the human
cost of deadly arrhythmias, including TdP and sudden cardiac death.
Project Outcome Goals
Both short- and long-term goals were benchmarked for this project. Short-term goals
were constantly re-evaluated throughout the first 4 weeks after the initiation of the clinical
practice portion of the project. Consecutive assessments were discussed with the ED outcome

PSYCHOTROPIC DRUGS AND QTc IN THE ED

13

stakeholders. Short-term goals included determining selective psychiatric patients aged 18 years65 years of age, those with one or more psychiatric diagnosis, and those currently prescribed and
taking psychotropic medications when admitted into the ED. Once confirmation was positive in
all categories, a 12-lead ECG was performed within the first 30 minutes and presented to the ED
physician for reading and assessment of QT/QTc prolongation.
Long-term goals were evaluated 6 weeks following initiation of the clinical practice
project and completed February 24, 2021. Long-term goals included establishing the current
guidelines and recommendations from the FDA, the American Heart Association (AHA), and the
American College of Cardiology Foundation (ACCF) for a QTc prolongation > 500 ms. If a
patient met that criteria, the patient would be educated and contact would be made with their
psychiatric provider.
Process Indicator Data Monitoring
The first process indicators used to translate this current evidence into practice took the
form of education workshops for ED staff on the rationale and importance of detecting a
prolongated QT/QTc of those at moderate and high risk. The impact of patient/family and ED
staff education on psychotropic medications was the focus of this evidence-based project.
Essential follow up consisted of viewing identified patient data. Obtaining ED staff feedback was
important to maintain best practice and retention of daily goals. Bi-weekly in-person meetings
with staff were maintained in order to be attentive to their concerns, questions, observations, and
commentary.
Outcome Indicator Data Monitoring
The outcome indicator used to translate this current evidence into clinical practice was
evaluating the number of patients aged 18 years–65 years of age with one or more psychiatric
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diagnoses and taking one or more psychotropic medications. An average number of 10 patients
per week are admitted into the ED for drug or alcohol-induced overdose, suicidal ideation or
suicide attempt, self-harming behaviors, or brought in by law enforcement under California’s
Welfare and Institution Code 5150 for detention of a mentally disordered persons for evaluation.
Outcome data were collected biweekly.
Results
Results were analyzed for process and outcome indicator data by assessing the average
number of weekly patients meeting the specific criteria for a total of 50 patients. While this
project primarily focused on medication statistics, the traits related to gender and age were
deemed important to capture. The conclusions resulted from calculations and graphing in Excel.
Psychiatric medications were considered for their potential to cause prolongation of the
QT/QTc interval and sudden cardiac death; those not meeting this stipulation were not included.
The seven SGADs and nine SGAPs) were examined (AZCERT, 2013). The cardiac rhythm on
the ECG was analyzed and documented as displaying sinus bradycardia (n7), regular sinus
rhythm (n17), sinus tachycardia (n24), atrial fibrillation with rapid ventricular response (n1), or
regular sinus rhythm with sinus arrythmia (n1). Table 2 displays the raw data collected on Day 1
of admission to the ED.
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Raw Data
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For most of the sample, their QT and QTc measurements had largely parallel trendlines.
The space between each trendlines averaged to be 70.5ms; the difference between the QTc
average of 414.28ms and the QT average of 343.78ms (Figure 1).
Figure 1
QT and QTc Measurements for All Patients
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The ages of the patients ranged from 18 years-65 years of age. There did not appear to be
any relationship between age and QTc measurements based on the distribution (Figure 2). The
uniformity of the data was a positive sign as there was no skewing nor evident trends due to age.
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QTC Measurements by Age
600

500

QTc (ms)

400

300

200

100

0
18 18 18 20 21 21 22 23 25 27 28 29 32 35 38 39 41 45 49 54 56 58 59 63 65

Age
Of the 50 patients, 23 were female and 27 were male. When compared, females had a
slightly longer average QTc (420.70 ms) compared to the males (408.81 ms); however, current
literature indicates that males may have longer QT/QTc without the influence of psychiatric
medication.
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Figure 3

Gender

Average QTc Based on Gender

408.81

Male

420.70

Female

402.00 404.00 406.00 408.00 410.00 412.00 414.00 416.00 418.00 420.00 422.00

QTc (ms)
This introduces the first limitation to the modest data pool, for as previously stated, males
genetically have longer baseline QTc measurements than females. If this project were repeated or
expanded, a more robust sample might reveal true differences between the prolongations of
males and females. By analyzing each gender separately, the project’s findings would likely be
explained by pre-existing differences. Males and females appeared to have similar numbers in
the 350-399ms range, but male patients were more likely to be in the 400-449ms range.
Figure 4
QTc Distribution Among Male Patients
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Figure 5
QTc Distribution Among Female Patients
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The exact capture of patient diagnoses in relation to their potential for cardiac conduction
abnormalities did not have a significant role on the relationships between psychotropic
medications and the patient population’s QTc measurements. Data were collected in an ED
setting and therefore the noting of cardiac rhythms and various diagnoses are standard when
performing an EKG.
The psychotropic medications were grouped into two categories: second-generation
antipsychotics and second-generation antidepressants. The antipsychotic medications considered
were Risperidone (dopamine, serotonin, norepinephrine receptor antagonist [DSNRAn]/serotonin-dopamine antagonist), Quetiapine (dopamine, serotonin multimodal [DS-MM],
serotonin-dopamine antagonist), Thioridazine (dopamine and serotonin receptor
antagonist/dopamine 2 antagonist), and Haldol (dopamine receptor antagonist [DRAn]/dopamine 2 antagonist). The second-generation antidepressants noted were Citalopram
(serotonin reuptake inhibitor [S-RI]/selective serotonin reuptake inhibitor [SSRI]), Escitalopram
(serotonin reuptake inhibitor [S-RI]/selective serotonin reuptake inhibitor [SSRI]), Fluoxetine
(serotonin reuptake inhibitor [S-RI]/selective serotonin reuptake inhibitor [SSRI]), Sertraline
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(serotonin reuptake inhibitor [S-RI]/selective serotonin reuptake inhibitor [SSRI]), Paroxetine
(serotonin reuptake inhibitor [S-RI]/selective serotonin reuptake inhibitor [SSRI]), and
Venlafaxine (serotonin and norepinephrine reuptake inhibitor [SN-RI]/dual serotonin and
norepinephrine reuptake inhibitor [SNRI]). While more than half of the sample was prescribed
more than one medication, 18 patients were taking one medication; 15 of those were taking a
sole antidepressant. No patient taking a medication of interest was exclusively on an
antipsychotic. The graph below displays the three patients with a corresponding drop from 18- to
15- (gray bars) in order to maintain the attention on the medications of focus. The highest QTc
measurements were taking Citalopram (489ms) and Fluoxetine (467ms). The lowest QTc
measurement came from one patient taking Risperidone (365ms). As expected, Citalopram has
been identified as the antidepressant with the most profound effect for increasing QTc. The
Fluoxetine patient was 41 years of age; an ideal patient to be monitored in primary care yearly.
The patient on Risperidone was one of the youngest at age 18 years. Risperidone is one of the
nine second generation antipsychotics on the list for prolonged QTc measurements. Neither of
the two patients on Risperidone had high QTc measurements. These findings cannot be
generalized due to the small sample size.
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Figure 6
QTc Measurements Taken for Patients Taking a Single Medication
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The intention of this project was rule out QTc prolongation with each medication;
however, most patients were on two or more medications. For side-by-side comparisons, those
on more than one medication appear multiple times; therefore, the number of patients
represented in the graphs outnumber the number of patients in the sample.
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When examining the SGADs, Sertraline had the shortest average QTc length at 381ms.
Of the second-generation antidepressant medications, Sertraline is considered one of the safer
psychiatric medications.
Figure 7

Medications

QTc Measurements for Sertraline
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Citalopram had the longest average QTc length at 445.33ms and was the longest average
QTc length of all the medications of focus for this project.
Figure 8
QTc Measurements for Citalopram
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With the exception of Escitalopram, Citalopram appeared to have the longest QTc
lengths; however, QTc length with Escitalopram were nearly as long at 431.56ms, followed by
Quetiapine and Fluoxetine with average lengths of 431ms and 430.75, respectively.
Figure 9
QTc Measurements for Escitalopram
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Figure 10
QTc Measurements for Quetiapine
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Figure 11
QTc Measurements for Fluoxetine
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This EBP project’s limited data might suggest that Escitalopram is riskier when
compared to Citalopram, which contrasts with published data. Larger EBP projects or formal
research studies with an adequately powered sample size would likely confirm what is known in
the literature.
Three of the 50 patients were on Citalopram; however, nine of the patients are taking
Escitalopram. Conceivably, the small number of patients taking Citalopram have skewed the data
for patients taking Citalopram. The average QTc length for Quetiapine should have been on the
higher end of the spectrum but was not in this limited sample. Furthermore, Fluoxetine’s
resultant trailing of Quetiapine’s results was consistent with published data reflecting slightly
lower QTc elongations.
Escitalopram was the most common of the focus medications (N = 9). This particular
drug is a commonly prescribed psychotropic medication. The second most common focus
medication was Risperidone (N = 7). While Escitalopram is a common antidepressant,
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Risperidone is a common SGAP. Compared to the other psychotropic medications, the average
QTc for Risperidone was in the lower range at 385.29ms.
Figure 12
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The antipsychotic medication Thioridazine ha the shortest average QTc elongation in this
project at 368ms. When given in the appropriate dose, Thioridazine should not cause any
lengthening of the QTc. As only one patient is taking Thioridazine, the assumption is that this
patient was on a proper dose.
The three remaining medications (i.e., Paroxetine, Haldol, Venlafaxine) revealed QTc
lengths in the middle range of all observations.
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Figure 13
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Figure 14
QTc Measurements for Haldol

Medications

Haldol, Quetiapine

429
400

Haldol, Lamotrigine

389

Depakote, Haldol, Lithium

421

Haldol, Quetiapine
360

370

380

390

400

410

QTc (ms)

420

430

440

PSYCHOTROPIC DRUGS AND QTc IN THE ED

27

Figure 15
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As these three medications are not on the low end of the spectrum, caution should be
taken when prescribing and their potential effect on QTc should not be discounted.
In summary, the 10 medications examined in this EBP project included four
antipsychotic medications and six antidepressant medications. Altogether, their for average QTc
prolongations from least to greatest were: Thioridazine, Sertraline, Risperidone, Paroxetine,
Haldol, Venlafaxine, Fluoxetine, Quetiapine, Escitalopram, and Citalopram (Figure 16). Both
antipsychotic and antidepressant medications were dispersed throughout the sample and the
range of QTc lengths was 77.33ms (Range: Citalopram = 445.33ms, Thioridazine = 368ms).
Therefore, this small group were not likely to be reaching alarming QTc levels. Furthermore, the
spectrum of QTc levels for all the individuals was between the mid 300s to the mid 400s;
acceptable QTc levels. This group provided the spectrum of ages (18 years-65 years of age) with
a balanced gender distribution.

PSYCHOTROPIC DRUGS AND QTc IN THE ED

28

Figure 16
Average QTc Based on Medication
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Discussion and Sustainability
The implementation of this EBP project improved ED staff knowledge on the importance
of assessing and the analyzing the effects of second-generation antipsychotics and
antidepressants for rare cases where the QTc interval is greater than 500 ms. Many psychotropic
medications can delay cardiac repolarization thereby producing prolonged QTc and raising the
possibility of life-threatening progression to TdP, ventricular fibrillation, or sudden cardiac
death.
Barriers impeded successful implementation of this project:
1. In a high-volume ED, physicians did not consistently order the 12-lead ECG.
2. Patients might not have been forthcoming with their psychotropic medications or
neglected to report them thinking they were unrelated to their chief complaint.
3. The time and cost for an ECG.
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4. Lack of follow up or perceived risk of litigation for neglecting to interpret an ECG
not ordered by the physician could have complicated data collection.
5. Patients perceived as violent and non-compliant might not be able to undergo an
ECG, even if they were undergoing a cardiac event.
6. With the time constraints of a busy ED, provider and staff perception of the need for
the education department could have affected compliance.
To sustain this project, another DNP student at the University of San Diego Hahn School
of Nursing could adopt this as their own EBP project. That student would need an emergency
medicine background, be familiar with cardiac rhythms and ECG interpretation, and possess an
understanding of the neurochemistry underlying psychotropic medications. As an alternative, an
ED-based project champion could maintain the project and conduct education sessions for new
ED staff.
Implications for Practice
Healthy People 2030 included mental health with 15 baseline objectives focused on the
prevention, screening, assessment, and treatment of mental disorders and behavioral conditions
(Office of Disease Prevention and Health Promotion, n.d.). While the needed attention given to
mental health concerns in the United States continues to grow, specialty providers must also
consider the cardiac health implications of their psychiatric patients. The ED’s role is pivotal in
the assessment of psychiatric patients that may have an undiagnosed QT/QTc prolongation
attributed to their psychotropic medications.
Conclusion
Advanced practice nurses are positioned to understand the complexity of mental health
care and emergency medicine. This EBP project supported existing evidence, but the findings
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from a small patient sample are not generalizable. Continued sustainability of this project would
yield a larger sample over time to understand the characteristics of each of these medications in
the local population of ED patients. Goals of this project were to raise awareness in ED providers
to evaluate QTc measurements of their patients on psychotropic medications and to standardize
the use of 12-lead ECGs as part of the intake process.
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